anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention relates to processes for purifying acid stable phospholipase A2. Specifically, the invention relates to processes for the purification of phospholipase A2 form biological sources, such as non-pancreatic human sources which contain very small amounts of that enzyme. More specifically, this invention relates to the purification and characterization of phospholipase A2 from human platelets and from human rheumatoid synovial fluid. This invention also relates to polypeptides corresponding to at least a portion of the amino terminal amino acid sequence of human platelet and rheumatoid synovial fluid phospholipase A2 and antibodies thereto, as well as antibodies to purified, intact acid-stable phospholipase A2 for use in the treatment or diagnosis of inflammation and tissue injury associated with various diseases. And this invention relates to DNA sequences which encode these polypeptides. This invention further relates to methods for producing phospholipase A2 in hosts transformed with recombinant DNA molecules comprising those DNA sequences.
<P>PROBLEM TO BE SOLVED: To provide a technique suitable for massage agent for removing wrinkles and increasing only viscosity without increasing hardness of emulsified cosmetic.  <P>SOLUTION: An emulsifier type cosmetic comprises 45-60 mass% dextrin. The cosmetic is preferably a cosmetic for massage. The cosmetic preferably further contains 0.1-5 mass% corn starch. The corn starch is preferably pregelatinized by a heating step after the starch is dispersed into the cosmetic. The cosmetic is preferably, a cosmetic for massage for improving wrinkles and the objective wrinkles are preferably wrinkles existing in an extremely narrow corner part.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention relates to dental care agents provided in the form of single-portion capsules which consist of a water-soluble material and are filled with a flowable preparation for cleaning and/or caring for the oral cavity and/or the teeth. The capsule material is comprised entirely or predominantly of cellulose esters, polyvinyl alcohol, polyethylene oxide or mixtures thereof. The flowable preparation contains at least 50 wt. % of a humectant from the group of glycols, glycol ethers or polyols with 2-6 C atoms, of polyethylene glycols or a mixture thereof, and contains at least one flavoring substance and no more than 10 wt. % water. The capsule material is preferably comprised entirely or predominantly of methylhydroxypropyl cellulose.
FIELD: agriculture. SUBSTANCE: method involves addition of an effective microbial amount to feed diet promoting animal growth. Composition is a mixture of viable bacterium of species Enterococcus faecium 301, ATCC 55059 and Enterococcus faecium 202, ATCC 53518 and stearic acid dried microspheres. Stearic acid microspheres and viable bacteria are formed on rotating disk. Combination of microorganism sealed into stearic acid provides release of microorganisms in intestine being at necessary time without their preliminary releasing. EFFECT: increased weight gain, improved feed utility, increased meat yield. 15 cl, 5 dwg, 15 tbl
BACKGROUND: Symptom assessment is key to effective symptom management and palliative care for patients with advanced cancer. Symptom prevalence and severity estimates vary widely, possibly dependent on the assessment tool used. Are symptoms specifically asked about or must the patients add them as additional symptoms? This study compared the prevalence and severity of patient-reported symptoms in two different versions of a multi-symptom assessment tool. In one version, three symptoms dry mouth, constipation, sleep problems were among those systematically assessed, while in the other, these symptoms had to be added as an "Other problem".
METHODS: This retrospective cross-sectional study included adult patients with advanced cancer at an inpatient palliative care unit. Data were collected from two versions of the Edmonton Symptom Assessment System (ESAS): modified (ESAS-m) listed 11 symptoms and revised (ESAS-r) listed 9 and allowed patients to add one "Other problem". Seven similar symptoms were listed in both versions.
RESULTS: In 2013, 184 patients completed ESAS-m, and in 2017, 156 completed ESAS-r. Prevalence and severity of symptoms listed in both versions did not differ. In ESAS-m, 83% reported dry mouth, 73% constipation, and 71% sleep problems, but on ESAS-r, these symptoms were reported by only 3%, 15% and < 1%, respectively. Although ESAS-r severity scores for these three symptoms were higher than on ESAS-m, differences did not reach statistical significance.
CONCLUSION: We identified significant differences in patient symptom reporting based on whether symptoms like dry mouth, obstipation and sleep problems were specifically assessed or had to be added by patients as an "Other problem".
Augmented reality mobile application called "EyeCU" which simulates glaucoma progression and enhances understanding about the disease and its course. It is a bilingual (English/Spanish) application that is free-to-download on the Android and Apple app store. It will be delivered on a hospital owned tablet device and patients will be instructed to complete two sections, taking approximately 10 minutes.
Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of soy bread daily for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
Patients undergo collection of blood and urine samples on day 1. Patients also undergo clinical assessments, laboratory, radiographic, and other ancillary studies on day 1.
Functional dyspepsia (FD) is a common functional gastroduodenal disorder that has a great social and economic impact on patients. The pathophysiology of FD remains poorly understood and is most likely heterogeneous, but likely candidates are genetic factors, stress and duodenal luminal factors, including bile acids. Obeticholic acid (OCA), a Farnesoid X receptor (FXR) agonist, is an effective drug for primary biliary cirrhosis. Recently, it has been shown that OCA altered the gut microbiome via induction of lower endogenous bile acid levels in mice. OCA might alter the gut microbiota and duodenal inflammation. Moreover, gastric motility, accommodation and gastrointestinal peptide might be affected through the change in duodenal circumstances. Therefore, the aim of the current research protocol is to investigate the relationship between FXR agonist and gut microbiota, gastric motility, accommodation, and gastrointestinal peptide in healthy volunteers. During the screening of our healthy volunteers, the study will be explained, and the informed consent will be read together. When the volunteer agrees, it will be checked whether the volunteer is included, and some questionnaires will also be completed. A total of 20 healthy volunteers will be included and then randomized. All volunteers participate in both treatment arms: OCA or placebo. Participants will take each OCA and placebo for 21 days across the washout period at home. A motility test is performed before and at the end of each treatment. A high-resolution pressure gauge (HRM) catheter is placed into the proximal part of the small intestine (checked by fluoroscopy) and an intravenous catheter in the arm for blood sampling. The measurement in the fasted state will be performed until a characteristic cycle called as migrating motor complex cycle (MMC) is measured at least once. During migrating motor complex measurement, blood samples will be taken via a syringe that we connect to the line of your catheter every 20 min within the first 60min of MMC measurement, then every 10 min until the end of MMC phase III. Duodenal fluids are also aspirated and collected during the fasted state. From 30 minutes after the end of the MMC measurement, participants will start to drink a liquid nutrient meal at a constant speed while gastrointestinal motility continues to be monitored. In the meantime, a blood sample is taken every 10 minutes to measure hormones later. The measurement will finish 60 minutes after the start of the meal. During intragastric pressure measurement, participants must score their appetite feelings every 5 minutes on a scale questionnaire. An endoscopy is performed before and at the end of each treatment. Duodenal tissues (maximum 9) are collected using biopsy forceps via an endoscope. Participants will collect stool samples at home using the sampling material before taking the drug on day 1 and after taking the drug on days 2, 4, 7, 14, and 21.
Oxybutynin chloride, USP is an antispasmodic, muscarinic antagonist. Each oxybutynin chloride extended-release tablet, USP contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral administration. Oxybutynin chloride, USP is administered as a racemate of R- and S-enantiomers. 

Chemically, oxybutynin chloride, USP is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride. The empirical formula of oxybutynin chloride, USP is C22H31NO3•HCl. 

Its structural formula is:

Oxybutynin chloride, USP is a white crystalline solid with a molecular weight of 393.9. It is readily soluble in water and acids, but relatively insoluble in alkalis. 

Oxybutynin chloride extended-release tablets, USP also contains the following inert ingredients: hydrogenated vegetable oil, hypromellose, isopropyl alcohol, lactose monohydrate, methacrylic acid copolymer, microcrystalline cellulose, polysorbate 80, sodium lauryl sulfate, talc and triethyl citrate. The 5 mg tablets also contain D&C Red #27 and FD&C Blue #1. The 10 mg tablets also contain FD&C Red #40 and FD&C Yellow #6.

Meets USP Dissolution Test 7.

System Components and Performance 

Oxybutynin chloride extended-release tablet, USP uses a pH-independent hydrophilic matrix and pH dependent enteric coating to deliver oxybutynin chloride, USP at a controlled rate over approximately 24 hours. The oxybutynin chloride extended-release tablet, USP comprises of an inner core made of the drug, rate controlling pH independent polymer and other excipients. The tablet core is then coated with pH dependent enteric coating polymer. When tablets will be exposed to an acidic environment such as the stomach, the drug release will be minimal due to outer enteric coating of the pH dependent polymer. The outer enteric coating upon reaching an environment of pH 5.5 and above will start to dissolve and the polymer in the inner core tablet will hydrate to form a gel layer and the drug releases via diffusion process.
Thalidomide 50mg daily by mouth( increase 50mg after 2 weeks if tolerated until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if the patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/day, thalidomide discontinuation was allowed.
The application belongs to the technical field of genetic engineering, and particularly relates to a whitening short peptide and a preparation method thereof. The application provides a peptide, the amino acid sequence of which comprises a sequence shown as SEQ ID No. 1. The application also provides a polynucleotide for encoding the peptide, a recombinant expression vector containing the polynucleotide, a recombinant host cell containing the recombinant expression vector, a preparation method and application of the peptide, and a product containing the peptide and having the functions of whitening, inhibiting melanocytes or inhibiting melanin generation. The peptide provided by the application has similar sequence with MSH-alpha, good water solubility and strong stability. The preparation method of the peptide provided by the application has simple operation process, can utilize biological fermentation to carry out large-scale preparation, and has obvious cost advantage. The product produced by the preparation method of the peptide provided by the application has accurate molecular weight, high purity and no obvious impurity component.
Claustrophobia and disruptive patient motion are common impediments to MRI examination, but they may be prevented or ameliorated with a non-pharmacologic behavioral intervention administered by trained staff. The potential benefits of such an intervention are highly significant, considering that the alternatives are to cancel the study or administer sedation. Inability to complete their MRI scans adversely affects an estimated 700,000 patients every year in the US. These patients are either deprived of a diagnosis, subject to diagnostic delays, or are exposed to risks of pharmacologic sedation, including death. The imaging facilities in turn, typically cannot fill the suddenly vacated examination slots in time before the next scheduled patient and thus incur considerable lost revenue and efficiency. The long-term goal is to provide a validated, clinically feasible means for non-pharmacologic amelioration of claustrophobia and disruptive patient motion, achieved by training MRI staff to use advanced rapport skills and comforting language to help patients. Phase I will design and perform a formative evaluation of a Comfort Talk® Training intervention so that definitive testing of the hypothesized benefits for the intervention can be accomplished in Phase II.

In Specific Aim 1 the Comfort TalkTM intervention sequence will be designed to include training in advanced rapport skills, using basic comforting language and avoiding negative language for all facility staff (including receptionists, technologists, nurses, and physicians). A core of licensed healthcare professionals will be taught how to guide patients in self-hypnotic relaxation techniques, using scripts, found to be safe and effective in the radiology department. Techniques are designed to easily integrate into the normal workflow without adding time. Training will include 2x8 hrs live at three test sites. Acceptance, observation of staff behavior, qualitative feedback, and rates of noncompletion will be used to assess efficacy of training, guide prototype development, and develop train-the-trainer materials. Using in-market piloting techniques, niche applications with their metrics will be explored to develop situation-specific supplemental materials. In Aim 2 an interactive web-based electronic platform will be developed to supplement training and provide post-training support. It will provide scenarios and practice applications, guided dialogue options, functions for online live interactive classes, and interface with smartphones. The prototype will be beta-tested with 20 experts in hypnosis and refined through user input from the test sites. Aim 3 is to conduct a formative evaluation of the entire Comfort Talk® intervention. Effects will be evaluated in 3-months intervals and compared to baseline performance. Criteria will include acceptance, qualitative feedback, content mastery, staff behavior, rates of noncompletion, patient recall and satisfaction. Additional metrics identified through in-market exploration will be analyzed for their potential as economic drivers and evaluation instruments.
Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The means is used in outpatient and clinical practice in human and veterinary medicine. It has higher efficiency, simplified production and low costs. It contains the mineral clinoptilolite which is heat-treated and sterilized at 150 to 250 degrees C of particle sizes of ?0.1 mm, and of 0.01 to 10 wt. % natural biological additive. The latter includes, in wt. %: from 1 to 10 propolis, 0.1-1 attar of roses and from 1 to 10 lyophilizate of the blossom of Hipericum perforatum and/or of blossom of Matricaria chamomilla, and/or of blossom of Lavandula angustifolia, and/or of blossom of Achillea millefolium, and or of blossom of Calendula officinalis. 4 claims, 5 figures
BACKGROUND: The operative treatment for thoracic outlet syndrome (TOS) varies in the United States. This may be due to differences in specialty training of the provider. We sought to identify which procedures are primarily performed by specialty, identify patient characteristics presenting for different neurogenic TOS surgical interventions, and describe the safety of TOS surgery.
METHODS: Patients treated for neurogenic TOS between 2016 and 2018 were identified from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP). Patient characteristics, surgeon details, intraoperative variables, and complication outcomes were abstracted. Patient cohorts were stratified by type of operative intervention and by treating specialty.
RESULTS: Transthoracic first rib resection was the most common procedure performed for TOS relief (46.1%), followed by division of the scalene muscles with rib resection (23.9%) and brachial plexus exploration with decompression (19.4%). Vascular surgeons performed 87% of TOS repairs. Thirty-day complication rate was 3.5%. Addition of scalenectomy to first rib resection was common and resulted in increased operative time but did not increase early complication rate or readmission rate.
CONCLUSION: Patient characteristics and dispositions are similar between the various TOS operative approaches. All major surgical treatments for TOS have low complication rates. Transthoracic first rib resection performed by vascular surgeons remains the most common surgical treatment for patients with TOS in the United States. Despite neurogenic symptoms representing most cases, less than 10% of operations are performed by peripheral nerve specialists, highlighting a potential need for greater incorporation of TOS release into peripheral nerve practices.
The sessions for the HTG were conducted on horseback by a "leader", "side walker", and "physiotherapist" while the child was mounted on the horse. Before mounting, the child was dressed in the safety equipment of a helmet and rider vest by the physiotherapist and was directed to mount the horse from the mounting steps. In the first week of training, the cases received adaptation training. Within the training, 7 min of simple sitting on the horse were performed. In this position, the child was able to caress the horse's neck with one or both hands, rest while the horse walked, and 10 standing (or for those who could not do this, the horse was in a standing position)n the stirrups exercises were performed while holding the retaining strap.
Participants will complete initial assessments and then take part in a 3-month intervention consisting of 12 weekly individual therapy sessions with daily RR app use between sessions. At the end of the 3-month intervention period, an exit interview will be conducted and participants will complete a second assessment consisting of questionnaires and an ED diagnostic interview, a blood specimen for HbA1c, and 3-days of blinded CGM monitoring. Participants will then enter a 6-month follow-up period during which time they may continue to use the app, but will no longer attend individual sessions. Participants will be return to the clinic at 6 and 9 months for follow-up.
BACKGROUND: Current guidelines recommend revascularization in patients with ischemic cardiomyopathy (ICM). However, there is limited information about the trends and outcomes of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in ischemic cardiomyopathy patients with multivessel coronary artery disease.
METHODS AND RESULTS: Using New Jersey state mandatory registries, 8083 patients with ischemic cardiomyopathy with CABG or PCI revascularization for multivessel coronary artery disease from 2007 to 2018 were included in the analysis. Joinpoint regression and multivariable logistic regression analyses were performed to assess the annual percentage change in trends and predictors of the 30-day mortality rate, respectively. A decline in CABG procedures was observed from 2007 to 2011 (annual percentage change, -11.5%; P=0.003), followed by stabilization. The PCI trend remained unchanged from 2007 to 2010 and then increased significantly (annual percentage change, 3.2%; P=0.02). In the subsample of patients with proximal left anterior descending artery plus circumflex and right coronary artery, CABG was a predominant procedure until 2011, and the proportion of both procedures did not differ thereafter. In the subsample of patients with left anterior descending artery and any other artery stenosis, PCI remained dominant from 2007 to 2018, while in patients with left main and any other artery stenosis, CABG remained dominant from 2007 to 2018 (P<0.001). The 30-day risk-adjusted mortality rate was higher after PCI versus CABG for each year, but after adjustment for completeness of revascularization, there was no difference between groups.
CONCLUSIONS: The patterns of revascularization procedures for patients with ischemic cardiomyopathy with multivessel coronary artery disease have changed over the years, as evidenced by the changes in CABG and PCI trends. CABG and PCI had comparable 30-day risk-adjusted mortality risks.
Participants randomized to the control group will receive enhanced usual care (EUC). The EUC group will receive 8 sessions of standard Cognitive Behavioral Therapy.
Patients receive abemaciclib lead-in on days 1-14 and lutetium Lu 177 vipivotide tetraxetan IV over 30 minutes on day 15. Treatment repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Pseudoephedrine, like other CNS stimulants, has been abused. At high doses, subjects commonly experience an elevation of mood, a sense of increased energy and alertness, and decreased appetite. Some individuals become anxious, irritable, and loquacious. In addition to the marked euphoria, the user experiences a sense of markedly enhanced physical strength and mental capacity. With continued use, tolerance develops, the user increases the dose and toxic signs and symptoms appear. Depression may follow rapid withdrawal. Narcotic antitussives and stimulants, such as pseudoephedrine, are banned and tested for by the U.S. Olympic Committee (USOC) and the National Collegiate Athletic Association (NCAA).
There will be one treatment cohort. Radiation therapy will be delivered daily for 15 daily fractions, 2.67Gy per fraction, delivered using a 3-D or IMRT(Intensity Modulate Radiation Therapy) plan. For participants with high-risk features deemed by the radiation oncologist who would otherwise be a candidate for a boost (age \<50, high grade, poor biology, close margins), 48 Gy delivered in fifteen fractions of 3.2 Gy is allowed.